Insomnia Therapeutics Market Analysis North America, Asia, Europe, Rest of World (ROW) - US, Canada, France, Germany, Japan - Size and Forecast 2023-2027
| Published: Oct 2023 | Pages: 151 | SKU: IRTNTR76428 |
Insomnia Therapeutics Market Forecast 2023-2027
The Insomnia Therapeutics Market size is estimated to grow by USD 1.01 billion at a CAGR of 5.49% between 2022 and 2027.
There is a rising prevalence of insomnia across the globe. There are several factors that are resulting in the increasing prevalence of insomnia such as alterations in the way of life, including disturbed sleep habits, greater use of electronics before going to sleep, and high levels of stress. Other factors which are influencing insomnia can include medical problems, psychological illnesses, and specific drugs. As a result, there is an increasing demand for treatment of insomnia. The main advantage of therapeutics for insomnia is that it lessens its effects and enhances the quality of sleep. Some of the main examples of medications for insomnia include benzodiazepines, non-benzodiazepines, and orexin receptor antagonists.
What will be the Size of the Market During the Forecast Period?
To learn more about this report, Request Free Sample
Market Segmentation
Type Analysis
The drug segment is estimated to witness significant growth during the forecast period. The drug segment mainly comprises pharmaceutical drugs which are increasingly adopted to treat insomnia. These therapeutics can be classified into various classes, including sedative-hypnotics, benzodiazepines, non-benzodiazepines, melatonin receptor agonists, orexin receptor antagonists, and other medications.
Get a glance at the market contribution of various segments View a PDF Sample
The drug segment was the largest segment and was valued at USD 2.32 billion in 2017. One of the main types of medication is sedative-hypnotics which essentially acts as a central nervous system (CNS) depressant and helps in inducing sleep. Some of the main sedative-hypnotics that are frequently administered for insomnia include barbiturates like secobarbital and pentobarbital. Another significant classification of medication that boosts the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that has sedative, hypnotic, anxiolytic, and muscle-relaxing properties in the brain is benzodiazepines. Hence, the increasing adoption of such medication for the treatment of insomnia is expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.
Distribution Channel Analysis
The prescription segment mainly comprises a group of pharmaceuticals that are prescribed by medical practitioners to treat insomnia. Insomnia can be referred to as a sleep disorder which includes symptoms such as problems going to sleep, staying asleep, or both. As a result, it leads to insufficient sleep and impairment of daytime function. There is an increasing adoption of this segment to lengthen and increase the quality of sleep, helping people with insomnia get a good night's rest. Some of the main drugs that are included in this segment include benzodiazepines, nonbenzodiazepines, melatonin agonists, and orexin receptor antagonists. Factors such as consumer demand for safe and efficient therapeutics for insomnia, as well as ongoing efforts in research and development to create novel treatments, are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.
Regional Analysis
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 60% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are significantly contributing to the growth of the insomnia treatment market in North America are the high prevalence of insomnia and the growing awareness of its negative effects of insomnia on the health and well-being of people who suffer from it.
In addition, there is a significant availability of various forms of prescription drugs, over-the-counter (OTC) drugs, and non-drug treatments in the region. Some of the prominent market players in North America that offer insomnia therapeutics include Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Merck and Co., Inc., Sanofi S.A., and Purdue Pharma L.P. In addition, there is an increase in investments in R&D by these companies to offer the market new and enhanced insomnia treatments. Hence, factors such as the increasing prevalence of insomnia and the growing demand for effective treatments are expected to drive market growth in the region.
Buy Now Full Report and Discover More
Key Insomnia Therapeutics Market Players
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Astellas Pharma Inc: The company offers insomnia therapeutics namely Myslee tablets.
- Abbott Laboratories
- Aurobindo Pharma Ltd.
- Eisai Co. Ltd.
- Electromedical Products International Inc.
- Idorsia Pharmaceuticals Ltd.
- INNOVATIVE NEUROLOGICAL DEVICES LLC
- Mallinckrodt Plc
- MEDICE Arzneimittel Putter GmbH and Co. KG
- Merck and Co. Inc.
- Minerva Neurosciences Inc.
- Neurim Pharmaceuticals Ltd.
- Pfizer Inc.
- Questex LLC
- Sanofi
- Sumitomo Pharma Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Vanda Pharmaceuticals Inc.
- Viatris Inc
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Market Dynamics
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Significant Trends
A key factor shaping the market growth is the increased focus on non-pharmacological treatments. There is a growing popularity for non-pharmacological therapies for insomnia across the international markets. Factors such as the rising awareness of the significance of addressing the underlying causes of insomnia and increased worry over the potential side effects and hazards associated with pharmacological treatments are significantly contributing to this trend.
Moreover, there is an increasing demand for cognitive behavioral therapy for insomnia (CBT-I) which is one of the major non-pharmacological treatments. The essential purpose of CBT-I is to recognize and alter the behaviors and thinking processes that lead to sleep problems. The success rate in improving the quality of sleep and reducing the symptoms of insomnia is fuelling its adoption. Hence, such factors are positively impacting the market which in turn will drive the market trends during the forecast period.
Major Challenges
Lack of awareness of insomnia as a disease is one of the key challenges hindering market growth. Some of the main obstacles faced by the market include the lack of understanding and stigma surrounding insomnia. In addition, several individuals are not aware of the seriousness of insomnia and how it can significantly impact their general health and well-being.
Moreover, a majority of the population tends to dismiss or overlook their sleeping troubles, considering them as minor inconveniences as opposed to major health risks. As a result, of such ignorance, it can lead to long-term effects on them and on society. Hence, such factors are negatively impacting the market which in turn will hinder the market growth during the forecast period.
Buy Now Full Report and Discover More
Key Customer Landscape
The market growth and forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
Market Analyst Overview
The Insomnia Therapeutics Market experiences robust growth driven by factors like rising stress levels and the American Academy of Sleep Medicine's (AASM) Sleep Prioritization Survey 2020 revealing concerns about adults' sleep quality and ability to fall asleep. Increased awareness about treatment options, highlighted by articles like those in Springer, counters misconceptions about insomnia's severity. Innovative products like Pear Therapeutics' FDA-authorized digital therapeutics, such as Somryst, offer promise for chronic insomnia, anxiety, and depression. The Orexin Antagonist Segment sees advancements with drugs like suvorexant, lemborexant, and daridorexant, targeting orexin-A and B neuropeptides, and regulating the arousal system. Companies like Idorsia Pharmaceuticals and Eisai Limited lead in product development, aiming to address insomnia disorder with effective and safe treatment options.
Segment Overview
The market research and growth report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
- Type Outlook (USD Million, 2017 - 2027)
- Drug
- Devices
- Distribution Channel Outlook (USD Million, 2017 - 2027)
- Prescription
- OTC
- Geography Outlook (USD Million, 2017 - 2027)
- North America
- The U.S.
- Canada
- Europe
- The U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- ROW
- Australia
- Argentina
- Brazil
- North America
|
Insomnia Therapeutics Market Scope |
|
|
Market Report Coverage |
Details |
|
Page number |
151 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.49% |
|
Market growth 2023-2027 |
USD 1,002.93 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
5.15 |
|
Regional analysis |
North America, Asia, Europe, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 60% |
|
Key countries |
US, Canada, France, Germany, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, Astellas Pharma Inc., Aurobindo Pharma Ltd., Eisai Co. Ltd., Electromedical Products International Inc., Idorsia Pharmaceuticals Ltd., INNOVATIVE NEUROLOGICAL DEVICES LLC, Mallinckrodt Plc, MEDICE Arzneimittel Putter GmbH and Co. KG, Merck and Co. Inc., Minerva Neurosciences Inc., Neurim Pharmaceuticals Ltd., Pfizer Inc., Questex LLC, Sanofi, Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., and Viatris Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our market growth analysis report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
What are the Key Data Covered in this Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the market between 2023 and 2027
- Precise estimation of the market size and its contribution to the market in focus on the parent market
- Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
- Companies landscape comparing criticality of inputs and factors of differentiation
- Exclusive Matrix on companies' position and classification
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the market across North America, Asia, Europe, and the Rest of the World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of market companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global insomnia therapeutics market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global insomnia therapeutics market 2017 - 2021 ($ million)
- 4.2 Type Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million)
- 4.3 Distribution channel Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Type
- 6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
- 6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type
- 6.3 Drug - Market size and forecast 2022-2027
- Exhibit 34: Chart on Drug - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Drug - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Drug - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Drug - Year-over-year growth 2022-2027 (%)
- 6.4 Devices - Market size and forecast 2022-2027
- Exhibit 38: Chart on Devices - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Devices - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Devices - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Devices - Year-over-year growth 2022-2027 (%)
- 6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ million)
- Exhibit 43: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Exhibit 44: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 45: Data Table on Distribution Channel - Market share 2022-2027 (%)
- 7.2 Comparison by Distribution Channel
- Exhibit 46: Chart on Comparison by Distribution Channel
- Exhibit 47: Data Table on Comparison by Distribution Channel
- 7.3 Prescription - Market size and forecast 2022-2027
- Exhibit 48: Chart on Prescription - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Prescription - Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Prescription - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Prescription - Year-over-year growth 2022-2027 (%)
- 7.4 OTC - Market size and forecast 2022-2027
- Exhibit 52: Chart on OTC - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on OTC - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on OTC - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on OTC - Year-over-year growth 2022-2027 (%)
- 7.5 Market opportunity by Distribution Channel
- Exhibit 56: Market opportunity by Distribution Channel ($ million)
- Exhibit 57: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 59: Chart on Market share by geography 2022-2027 (%)
- Exhibit 60: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 61: Chart on Geographic comparison
- Exhibit 62: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Asia - Market size and forecast 2022-2027
- Exhibit 67: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 68: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.5 Europe - Market size and forecast 2022-2027
- Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 Canada - Market size and forecast 2022-2027
- Exhibit 83: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Canada - Year-over-year growth 2022-2027 (%)
- 9.9 Japan - Market size and forecast 2022-2027
- Exhibit 87: Chart on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on Japan - Year-over-year growth 2022-2027 (%)
- 9.10 France - Market size and forecast 2022-2027
- Exhibit 91: Chart on France - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on France - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on France - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on France - Year-over-year growth 2022-2027 (%)
- 9.11 Germany - Market size and forecast 2022-2027
- Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 99: Market opportunity by geography ($ million)
- Exhibit 100: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 101: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 103: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 104: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 105: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 106: Matrix on vendor position and classification
- 12.3 Astellas Pharma Inc.
- Exhibit 107: Astellas Pharma Inc. - Overview
- Exhibit 108: Astellas Pharma Inc. - Product / Service
- Exhibit 109: Astellas Pharma Inc. - Key news
- Exhibit 110: Astellas Pharma Inc. - Key offerings
- 12.4 Aurobindo Pharma Ltd.
- Exhibit 111: Aurobindo Pharma Ltd. - Overview
- Exhibit 112: Aurobindo Pharma Ltd. - Product / Service
- Exhibit 113: Aurobindo Pharma Ltd. - Key offerings
- 12.5 Eisai Co. Ltd.
- Exhibit 114: Eisai Co. Ltd. - Overview
- Exhibit 115: Eisai Co. Ltd. - Business segments
- Exhibit 116: Eisai Co. Ltd. - Key offerings
- Exhibit 117: Eisai Co. Ltd. - Segment focus
- 12.6 Electromedical Products International Inc.
- Exhibit 118: Electromedical Products International Inc. - Overview
- Exhibit 119: Electromedical Products International Inc. - Product / Service
- Exhibit 120: Electromedical Products International Inc. - Key offerings
- 12.7 Idorsia Pharmaceuticals Ltd.
- Exhibit 121: Idorsia Pharmaceuticals Ltd. - Overview
- Exhibit 122: Idorsia Pharmaceuticals Ltd. - Product / Service
- Exhibit 123: Idorsia Pharmaceuticals Ltd. - Key offerings
- 12.8 INNOVATIVE NEUROLOGICAL DEVICES LLC
- Exhibit 124: INNOVATIVE NEUROLOGICAL DEVICES LLC - Overview
- Exhibit 125: INNOVATIVE NEUROLOGICAL DEVICES LLC - Product / Service
- Exhibit 126: INNOVATIVE NEUROLOGICAL DEVICES LLC - Key offerings
- 12.9 Merck and Co. Inc.
- Exhibit 127: Merck and Co. Inc. - Overview
- Exhibit 128: Merck and Co. Inc. - Business segments
- Exhibit 129: Merck and Co. Inc. - Key news
- Exhibit 130: Merck and Co. Inc. - Key offerings
- Exhibit 131: Merck and Co. Inc. - Segment focus
- 12.10 Minerva Neurosciences Inc.
- Exhibit 132: Minerva Neurosciences Inc. - Overview
- Exhibit 133: Minerva Neurosciences Inc. - Product / Service
- Exhibit 134: Minerva Neurosciences Inc. - Key offerings
- 12.11 Neurim Pharmaceuticals Ltd.
- Exhibit 135: Neurim Pharmaceuticals Ltd. - Overview
- Exhibit 136: Neurim Pharmaceuticals Ltd. - Product / Service
- Exhibit 137: Neurim Pharmaceuticals Ltd. - Key offerings
- 12.12 Pfizer Inc.
- Exhibit 138: Pfizer Inc. - Overview
- Exhibit 139: Pfizer Inc. - Product / Service
- Exhibit 140: Pfizer Inc. - Key news
- Exhibit 141: Pfizer Inc. - Key offerings
- 12.13 Sanofi
- Exhibit 142: Sanofi - Overview
- Exhibit 143: Sanofi - Business segments
- Exhibit 144: Sanofi - Key news
- Exhibit 145: Sanofi - Key offerings
- Exhibit 146: Sanofi - Segment focus
- 12.14 Sumitomo Pharma Co. Ltd.
- Exhibit 147: Sumitomo Pharma Co. Ltd. - Overview
- Exhibit 148: Sumitomo Pharma Co. Ltd. - Business segments
- Exhibit 149: Sumitomo Pharma Co. Ltd. - Key offerings
- Exhibit 150: Sumitomo Pharma Co. Ltd. - Segment focus
- 12.15 Sun Pharmaceutical Industries Ltd.
- Exhibit 151: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 152: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 153: Sun Pharmaceutical Industries Ltd. - Key offerings
- 12.16 Takeda Pharmaceutical Co. Ltd.
- Exhibit 154: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 155: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 156: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 157: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 12.17 Vanda Pharmaceuticals Inc.
- Exhibit 158: Vanda Pharmaceuticals Inc. - Overview
- Exhibit 159: Vanda Pharmaceuticals Inc. - Product / Service
- Exhibit 160: Vanda Pharmaceuticals Inc. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 161: Inclusions checklist
- Exhibit 162: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 163: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 164: Research methodology
- Exhibit 165: Validation techniques employed for market sizing
- Exhibit 166: Information sources
- 13.5 List of abbreviations
- Exhibit 167: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
insomnia therapeutics market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis